Advancing Long COVID Research: The Critical Role of Biospecimens in Understanding Post-Acute Sequelae

Introduction

Long COVID, formally known as post-acute sequelae of SARS-CoV-2 infection (PASC), continues to affect millions of individuals across the United States even as the pandemic phase transitions to endemic circulation. Research estimates suggest that 10-30% of individuals who experience confirmed COVID-19 infection develop persistent symptoms lasting weeks to months after initial infection, creating an urgent need for diagnostic tools, therapeutic interventions, and comprehensive understanding of disease mechanisms.^1,2 Access to well-characterized biospecimens from patients with confirmed long COVID remains essential for advancing this critical field of research.

The heterogeneous nature of long COVID — encompassing cardiovascular, neurological, immunological, and metabolic complications — demands longitudinal specimen collections paired with detailed clinical annotation to unravel underlying pathophysiology. From study design to receipt of samples, researchers require biospecimen resources that capture the natural history of post-acute disease while enabling biomarker discovery and therapeutic validation studies.

Understanding Long COVID: Clinical Manifestations and Research Needs

Long COVID encompasses a diverse array of persistent symptoms following acute SARS-CoV-2 infection. Common manifestations include fatigue, cognitive dysfunction (“brain fog”), dyspnea, chest pain, palpitations, headache, and exercise intolerance.³ These symptoms can occur regardless of initial disease severity, affecting individuals who experienced mild, moderate, or severe acute COVID-19.

Recent systematic reviews have identified several key symptom clusters in long COVID patients, with fatigue representing the most prevalent complaint across studies. Neurological symptoms, including cognitive impairment and headaches, affect a substantial proportion of patients and significantly impact quality of life and functional capacity.⁴ Cardiovascular complications, including postural orthostatic tachycardia syndrome (POTS) and myocarditis, have emerged as particularly concerning sequelae requiring ongoing research attention.

Research priorities in long COVID include:

Biomarker Discovery: Identifying diagnostic, prognostic, and predictive biomarkers that can stratify patients, predict natural history, and guide therapeutic interventions. Promising markers under investigation include inflammatory cytokines (IL-6, TNF-α), endothelial dysfunction markers, and immune dysregulation signatures.⁵

Mechanistic Studies: Understanding viral persistence, autoimmune activation, endothelial dysfunction, microbiome alterations, and mitochondrial dysfunction that may drive persistent symptoms. Access to matched sample sets including plasma, serum, PBMCs, and other matrices enables comprehensive mechanistic investigation.

Therapeutic Development: Supporting clinical trials and drug development programs targeting long COVID symptoms and underlying pathophysiology. Well-characterized patient cohorts with documented treatment responses provide invaluable resources for validation studies.

Risk Stratification: Identifying host genetic factors, pre-existing conditions, and acute infection characteristics that predict long COVID development. Genomic annotation paired with clinical outcomes data enables precision medicine approaches.

The Role of Biospecimens in Long COVID Research

Longitudinal biospecimen collections represent gold-standard resources for long COVID research, enabling investigators to track immune dynamics, inflammatory markers, and molecular signatures over time. Serial collections from the same patient at multiple timepoints — acute infection, convalescence, and long COVID phases — provide powerful tools for understanding disease progression and recovery trajectories.

Essential Specimen Types for Long COVID Research

Plasma and Serum Specimens

High-quality plasma and serum enable quantification of cytokines, chemokines, antibody responses, viral antigens, and other soluble mediators. Studies have demonstrated elevated inflammatory markers including IL-6, C-reactive protein, and D-dimer in subsets of long COVID patients, suggesting ongoing inflammation months after acute infection.⁶ Access to frozen aliquots with standardized collection protocols ensures reproducible biomarker measurements across platforms.

Explore plasma specimens

Peripheral Blood Mononuclear Cells (PBMCs)

Cryopreserved PBMCs support immune phenotyping, T-cell and B-cell repertoire analysis, and functional studies. Research indicates that long COVID patients may exhibit persistent immune activation, T-cell exhaustion, and altered immune cell populations detectable by flow cytometry and single-cell sequencing.⁷ Access to viable PBMCs with documented recovery rates enables advanced immunological characterization.

View PBMC products

Whole Blood Specimens

Whole blood collections enable RNA sequencing, genomic analysis, and comprehensive blood chemistry panels. Transcriptomic profiling of long COVID patients has revealed distinct gene expression signatures associated with symptom severity and duration, providing mechanistic insights and potential therapeutic targets.⁸

Browse whole blood specimens

Critical Annotation for Long COVID Biospecimens

The value of long COVID biospecimens extends far beyond the physical samples themselves. Comprehensive clinical and molecular annotation transforms biospecimens into powerful translational research tools. Essential data elements include:

Acute Infection Characteristics:

• Confirmed COVID-19 diagnosis date and testing method
• Initial symptom onset and severity
• Hospitalization status and interventions required
• Viral variant information when available

Long COVID Symptom Documentation:

• Persistent symptom onset and duration
• Symptom severity scores and validated questionnaires
• Organ system involvement (cardiovascular, neurological, pulmonary, etc.)
• Impact on functional capacity and quality of life

Treatment History:

• Acute phase treatments (antivirals, corticosteroids, other medications)
• Long COVID symptom management approaches
• Response to interventions

Vaccination Status:

• COVID-19 vaccine type and dates
• Vaccination timeline relative to infection
• Breakthrough infection status

Outcomes Data:

• Natural history over time
• Recovery trajectories and timelines
• Biomarker changes with treatment or over time
• Development of new complications

Emerging Research Findings in Long COVID

Recent research utilizing well-characterized biospecimens has illuminated several promising avenues for understanding and treating long COVID:

Immune Dysregulation: Studies have identified persistent immune activation markers including elevated inflammatory cytokines, altered T-cell populations, and autoantibody production in subsets of long COVID patients. These findings suggest potential therapeutic targets for immune-modulating interventions.⁹

Endothelial Dysfunction: Evidence of ongoing vascular dysfunction and endothelial activation months after acute infection correlates with cardiovascular symptoms and exercise intolerance. Biomarker panels assessing endothelial health may enable early identification of patients at risk for cardiovascular complications.¹⁰

Viral Persistence: Investigations using patient tissue and blood specimens have detected SARS-CoV-2 viral antigens and RNA in some long COVID patients months after initial infection, raising questions about viral reservoir sites and potential role in symptom persistence.¹¹

Metabolic Alterations: Metabolomic profiling reveals disrupted energy metabolism and mitochondrial dysfunction in long COVID patients, potentially explaining fatigue and exercise intolerance. These findings open new therapeutic possibilities targeting metabolic pathways.

Supporting Long COVID Research: From Basic Discovery to Clinical Translation

Organizations supporting infectious disease research, including SanguineBio, provide prospective biospecimen collection services tailored to long COVID study requirements. Custom cohort recruitment enables precise matching to inclusion/exclusion criteria, symptom profiles, and collection timepoints aligned with study designs.

Access to patients across the United States through established donor networks facilitates rapid cohort assembly while maintaining rigorous quality standards. From study design to receipt of samples, streamlined processes ensure research timelines remain on track while delivering biospecimens meeting specifications for downstream applications.

For researchers requiring existing inventories, curated collections of long COVID specimens with comprehensive annotation provide immediate access to well-characterized samples. Check our inventory to explore available long COVID biospecimen options.

The Path Forward: Precision Medicine for Long COVID

As research continues to unveil the complexity of post-acute COVID-19 sequelae, the importance of high-quality biospecimens paired with deep phenotyping becomes increasingly clear. Precision medicine approaches that leverage genomic profiling, immune signatures, and metabolic phenotypes hold promise for stratifying patients and personalizing therapeutic strategies.

Future directions in long COVID research include:

• Development of validated diagnostic biomarker panels
• Identification of therapeutic targets through multi-omics approaches
• Clinical trials testing immune-modulating, anti-inflammatory, and metabolism-targeting interventions
• Predictive models for long COVID risk assessment
• Long-term natural history studies tracking recovery and complications

The urgency of addressing long COVID cannot be overstated, with millions of individuals affected and healthcare systems managing the ongoing burden of post-acute sequelae. Robust biospecimen resources, coupled with collaborative research efforts, will accelerate progress toward effective diagnostics and treatments.

Conclusion

Long COVID research demands access to high-quality, well-annotated biospecimens that capture the natural history of this complex condition. Longitudinal collections from patients with confirmed SARS-CoV-2 infection and documented persistent symptoms provide invaluable resources for biomarker discovery, mechanistic studies, and therapeutic development. As the scientific community works to unravel the mysteries of post-acute COVID-19 sequelae, investment in comprehensive biospecimen resources will prove essential to achieving breakthroughs that improve patient outcomes.

Learn more about our infectious disease biospecimen portfolio.

---

References

1. CDC. Post-COVID Conditions. Centers for Disease Control and Prevention. Updated 2024. Accessed December 9, 2024. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/
2. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146. doi:10.1038/s41579-022-00846-2
3. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615. doi:10.1038/s41591-021-01283-z
4. Groff D, Sun A, Ssentongo AE, et al. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. JAMA Netw Open. 2021;4(10):e2128568. doi:10.1001/jamanetworkopen.2021.28568
5. Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. Trends Immunol. 2022;43(4):268-270. doi:10.1016/j.it.2022.02.008
6. Queiroz MAF, Neves PDMM, Lima SS, et al. Cytokine Profiles Associated With Acute COVID-19 and Long COVID-19 Syndrome. Front Cell Infect Microbiol. 2022;12:922422. doi:10.3389/fcimb.2022.922422
7. Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23(2):210-216. doi:10.1038/s41590-021-01113-x
8. Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881-895.e20. doi:10.1016/j.cell.2022.01.014
9. Klein J, Wood J, Jaycox JR, et al. Distinguishing features of Long COVID identified through immune profiling. Nature. 2023;623(7985):139-148. doi:10.1038/s41586-023-06651-y
10. Raman B, Bluemke DA, Lüscher TF, Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur Heart J. 2022;43(11):1157-1172. doi:10.1093/eurheartj/ehac031
11. Proal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Front Microbiol. 2021;12:698169. doi:10.3389/fmicb.2021.698169